Biographies
Team Members

Professor Neil Carragher
Researcher

Neil Carragher is Professor of Drug Discovery at the University of Edinburgh. He previously held postdoctoral positions within the University of Washington, Seattle and the Beatson Institute for Cancer Research, Glasgow. He also spent over 10 years in big-pharma with Yamanouchi (now astellas) and AstraZeneca. His primary research interests include advancing cell based assay screening technologies and high-content analysis for drug discovery and he will apply these technologies to support high throughput drug screening in the RRD centre.

His research has contributed to the discovery and translation of several agents into clinical trials including NXP900 currently in phase 1 oncology trials: https://www.clinicaltrials.gov/study/NCT05873686 and drug repurposing clinical trials in motor neuron disease: https://www.clinicaltrials.gov/study/NCT04302870. Neil is also co-founder of the spin-out company: PhenoTherapeutics Ltd. developing novel treatments for neurodegenerative disorders: https://www.phenotherapeutics.com/

Professor Neil Carragher is Professor of Drug Discovery at the University of Edinburgh. He previously held postdoctoral positions at the University of Washington, Seattle, and the Beatson Institute for Cancer Research in Glasgow. Prior to his academic career, he spent over a decade in the pharmaceutical industry with Yamanouchi (now Astellas) and AstraZeneca.

Neil’s research focuses on advancing cell-based assay screening technologies and high-content analysis to support drug discovery. At the RRD Centre, he will apply these technologies to enable high-throughput drug screening.

His work has contributed to the development of several agents now in clinical trials, including NXP900 (Phase 1, oncology: NCT05873686) and repurposed drugs for motor neuron disease (NCT04302870). Neil is also co-founder of PhenoTherapeutics Ltd., a spin-out company developing novel treatments for neurodegenerative disorders: www.phenotherapeutics.com.